Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

TVTX
Travere Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
May 9, 2025 3:59:57 PM EDT
19.99USD-2.202%(-0.45)1,260,672
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 8, 2025 9:15:30 AM EDT
20.34USD-0.489%(-0.10)0
After-hours
May 9, 2025 4:00:30 PM EDT
20.02USD+0.100%(+0.02)282,816
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 12, 2022
05:00PM EST  Travere Therapeutics Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Jan 10, 2022
07:33AM EST  Travere Therapeutics Sees FY2021 Sales $227.000M vs $227.00M Est   Benzinga
07:00AM EST  Travere Therapeutics Provides Corporate Update and 2022 Outlook   GlobeNewswire Inc
Jan 4, 2022
04:30PM EST  Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical   GlobeNewswire Inc
Dec 22, 2021
04:11PM EST  Travere Therapeutics 8-K Shows Co. Commercial Supply Deal With Catalent Pharma Solutions For Services Related To Processing, Packaging Of Sparsentan Tablets, No Terms Disclosed   Benzinga
Dec 16, 2021
08:08AM EST  Barclays Maintains Overweight on Travere Therapeutics, Raises Price Target to $40   Benzinga
04:34AM EST  SVB Leerink Maintains Outperform on Travere Therapeutics, Raises Price Target to $42   Benzinga
Dec 15, 2021
07:11AM EST  Travere Therapeutics Announces Topline Results From Ongoing Phase 1/2 COMPOSE Study Of Pegtibatinase In Classical Homocystinuria; Treatment With Highest Dose Pegtibatinase Led To 55% Mean Reduction In Total Homocysteine From Baseline   Benzinga
07:00AM EST  Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment   GlobeNewswire Inc
Dec 14, 2021
04:30PM EST  Travere Therapeutics Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Nov 11, 2021
04:30PM EST  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that management will present a Company overview at the following upcoming virtual investor conferences in November:   GlobeNewswire Inc
Oct 28, 2021
06:02PM EDT  Travere Therapeutics Q3 EPS $(0.13) Beats $(0.54) Estimate, Sales $68.22M Beat $60.93M Estimate   Benzinga
06:02PM EDT  CORRECTION: Travere Therapeutics Q3 EPS $(0.13) Beats $(0.54) Estimate, Sales $68.22M Beat $60.93M Estimate   Benzinga
04:19PM EDT  Travere Therapeutics Q3 EPS $(0.59) Misses $(0.54) Estimate, Sales $68.22M Beat $60.93M Estimate   Benzinga
04:18PM EDT  Travere Therapeutics Q3 EPS $(0.59) Misses $(0.54) Estimate, Sales $54.20M Miss $60.93M Estimate   Benzinga
12:04PM EDT  Travere Therapeutics's Return On Capital Employed Insights   Benzinga
08:26AM EDT  The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug   Benzinga
04:08AM EDT  Earnings Scheduled For October 28, 2021   Benzinga
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 22, 2021
10:22AM EDT  PleasrDAO Aint Nothing To F*** With: Wu Tang Clan Album Once Owned By Shkreli Has Been Purchased   Benzinga
Oct 14, 2021
04:30PM EDT  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.   GlobeNewswire Inc
Oct 13, 2021
05:00PM EDT  Travere Therapeutics Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Oct 12, 2021
05:00PM EDT  Travere Therapeutics Announces Transition of Chief Medical Officer   GlobeNewswire Inc
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
01:26AM EDT  Vifor Pharma Group and Travere Therapeutics Inc. (TVTX) have reached a joint collaboration and licensing agreement to commercialize sparsentan in Europe, Australia and New Zealand, the companies said in a statement.   RTTNews
01:04AM EDT  Vifor Pharma, Travere Announce Licensing Deal For Commercialization Of Sparsentan In Europe, Australia And New Zealand   RTTNews
01:00AM EDT  Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand   Business Wire
Sep 15, 2021
04:06PM EDT  Travere Therapeutics And Vifor Pharma Announce Licensing Agreement For The Commercialization Of Sparsentan In Europe, Australia And New Zealand   Benzinga
04:05PM EDT  Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand   GlobeNewswire Inc
Sep 14, 2021
04:30PM EDT  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Companys Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care delivery and health plan operations.   GlobeNewswire Inc
Sep 13, 2021
05:00PM EDT  Travere Therapeutics Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Sep 7, 2021
08:06AM EDT  Travere Therapeutics Announces Outcome Of Type A Meeting With FDA In Which Alignment Was Reached Plan To Submit Additional Estimated Glomerular Filtration Rate Data From The Phase 3 Duplex Study Of Sparsentan To Support An Application For 2022   Benzinga
08:00AM EDT  Travere Therapeutics Announces Successful Outcome from Type A   GlobeNewswire Inc
Aug 19, 2021
11:25AM EDT  Travere Therapeutics Sam.gov Contract For ~$15M Contract Via Dept. Of Veterans Affairs Federal Supply Schedule   Benzinga
Aug 17, 2021
04:36AM EDT  SVB Leerink Maintains Outperform on Travere Therapeutics, Raises Price Target to $37   Benzinga
Aug 16, 2021
02:55PM EDT  Ligand Pharma Highlights Partner Travere Therapeutics Topline Interim Results From Ongoing Phase 3 PROTECT Study Of Sparsentan; Co. Notes Is Entitled To Receive $5.9M Milestone Upon New Drug Application Submission   Benzinga
02:32PM EDT  Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet   Benzinga
01:12PM EDT  Hearing Canaccord Reiterates Buy Rating, $45 Price Target On Trevare Therapeutics; Calls PROTECT Data 'A Best-Case Scenario'   Benzinga
01:10PM EDT  California-based pharmaceutical company Travere Therapeutics, Inc. (TVTX) is up 13% in the Monday market after the company reported a successful positive result in phase three PROTECT study in IgA Nephropathy.   RTTNews
01:06PM EDT  UPDATE: Hearing Evercore Says Travere Therapeutics' 'Estimated Glomerular Filtration Rate Picture Seems Clear,' Totality Of Data For Co.'s Sparsentan Means Mgmt. Is 'now preparing for filing on the basis of accelerated approval'   Benzinga
01:02PM EDT  Hearing Evercore Raises Travere Therapeutics Price Target To $30; Unconfirmed   Benzinga
12:13PM EDT  Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump   Benzinga
10:22AM EDT  Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August   Benzinga
10:00AM EDT  Travere Therapeutics, Inc. (TVTX) shares are gaining more than 24 percent after the company reported positive interim results in phase 2 Protect study of Sparsentan in IgA Nephropathy.   RTTNews
07:16AM EDT  Travere Therapeutics Announces its PROTECT Study Met its Interim Primary Efficacy Endpoint   Benzinga
07:15AM EDT  Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy   Benzinga
07:00AM EDT  Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy endpoint achieved, p<0.0001   GlobeNewswire Inc
Jul 29, 2021
04:44PM EDT  Travere Therapeutics: Q2 Earnings Insights   Benzinga
04:43PM EDT  Travere Therapeutics Q2 EPS $(0.39) Beats $(0.68) Estimate, Sales $54.62M Beat $50.33M Estimate   Benzinga
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
04:23AM EDT  Earnings Scheduled For July 29, 2021   Benzinga
Jul 28, 2021
10:59AM EDT  Wu-Tang Clan Album Forfeited By Martin Shkreli Sold By US Justice Department   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
04:32PM EDT  Travere Therapeutics Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Jun 7, 2021
10:48PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (Travere or the Company) (NASDAQ:TVTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jun 4, 2021
08:08AM EDT  Travere Therapeutics Highlights Abstract Presentations At European Renal Association European Dialysis and Transplant Association Congress Jun. 5-7   Benzinga
08:00AM EDT  Travere Therapeutics Announces Presentation of Abstracts at   GlobeNewswire Inc
Jun 3, 2021
08:23AM EDT  The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout   Benzinga
Jun 2, 2021
11:02PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (Travere or the Company) (NASDAQ:TVTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
08:08AM EDT  Travere Therapeutics Says Completes Enrollment In Pivotal Phase 3 PROTECT Study Of Sparsentan In IgA Nephropathy   Benzinga
08:00AM EDT  Travere Therapeutics Completes Enrollment in Pivotal Phase 3   GlobeNewswire Inc
May 28, 2021
08:02AM EDT  The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq   Benzinga
May 27, 2021
04:30PM EDT  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in June:   GlobeNewswire Inc
09:16AM EDT  Canaccord Genuity Maintains Buy on Travere Therapeutics, Lowers Price Target to $45   Benzinga
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
May 26, 2021
02:34PM EDT  Mid-Afternoon Market Update: Build-A-Bear Rises After Q1 Results; Travere Therapeutics Shares Drop   Benzinga
12:25PM EDT  Mid-Day Market Update: Nasdaq Surges 70 Points; Larimar Therapeutics Shares Plummet   Benzinga
10:38AM EDT  Travere Therapeutics, Inc. (TVTX) shares are sliding more than 16 percent on Wednesday morning trade after the company said it no longer expects to submit for accelerated approval for its drug candidate Sparsentan as a treatment for focal segmental glomerulosclerosis or FSGS, a type of scarring in kidney, in the U.S. during the second half of 2021.   RTTNews
10:18AM EDT  Mid-Morning Market Update: Markets Mixed; Dick's Sporting Goods Beats Q1 Estimates   Benzinga
10:09AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2021   Benzinga
07:41AM EDT  Wedbush Downgrades Travere Therapeutics to Neutral, Announces $19 Price Target   Benzinga
07:33AM EDT  The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing   Benzinga
06:35AM EDT  Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data   Benzinga
May 25, 2021
04:05PM EDT  Travere Therapeutics Provides Regulatory Update On Sparsentan Development Program For Focal Segmental Glomerulosclerosis   Benzinga
04:01PM EDT  Travere Therapeutics Provides Regulatory Update on Sparsentan   GlobeNewswire Inc
May 17, 2021
10:16AM EDT  Canaccord Genuity Maintains Buy on Travere Therapeutics, Lowers Price Target to $48   Benzinga
May 6, 2021
04:24PM EDT  Retrophin Q1 EPS $(0.55) Misses $(0.39) Estimate, Sales $47.40M Miss $50.09M Estimate   Benzinga
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
May 5, 2021
10:08AM EDT  Retrophin Earnings Preview   Benzinga
Apr 26, 2021
04:30PM EDT  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.   GlobeNewswire Inc
Mar 1, 2021
05:27PM EST  Travere Therapeutics: Q4 Earnings Insights   Benzinga
04:08PM EST  Travere Therapeutics Q4 EPS $(2.37) Down From $(0.70) YoY, Sales $50.98M Miss $51.66M Estimate   Benzinga
04:01PM EST  Recently reported that ongoing DUPLEX Study of sparsentan in FSGS achieved interim proteinuria endpoint   GlobeNewswire Inc
03:51AM EST  Earnings Scheduled For March 1, 2021   Benzinga
Feb 26, 2021
10:18AM EST  A Preview Of Travere Therapeutics's Earnings   Benzinga
Feb 25, 2021
08:00AM EST  TravereTherapeutics Recognizes Rare Disease Day 2021   GlobeNewswire Inc
Feb 22, 2021
04:30PM EST  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in February and March:   GlobeNewswire Inc
Feb 19, 2021
07:25AM EST  The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko   Benzinga
Feb 18, 2021
04:36PM EST  Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy   Benzinga
Feb 17, 2021
04:05PM EST  Travere Therapeutics Announces Completion of Public Offering of   GlobeNewswire Inc
Feb 16, 2021
04:30PM EST  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2020 financial results on Monday, March 1, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.   GlobeNewswire Inc
Feb 12, 2021
05:59AM EST  Travere Therapeutics Priced 6,55M Share Public Offering of Common Stock @$26.75/Share   Benzinga
Feb 11, 2021
10:04PM EST  Travere Therapeutics Announces Pricing of Public Offering of   GlobeNewswire Inc
Feb 10, 2021
04:02PM EST  Travere Therapeutics Announces Proposed Public Offering $150M Of Common Stock   Benzinga
04:01PM EST  Travere Therapeutics Announces Proposed Public Offering of Common   GlobeNewswire Inc
Feb 3, 2021
11:34AM EST  Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $51   Benzinga
Feb 2, 2021
10:01AM EST  Shares of Travere Therapeutics, Inc. (TVTX) are rising more than 12% Tuesday morning on the news that its drug candidate, sparsentan achieved interim proteinuria endpoint in a late-stage study.   RTTNews
09:26AM EST  Travere Therapeutics Shares Rally On Interim Sparsentan Data In Late-Stage Kidney Disorder Study   Benzinga
08:05AM EST  The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment   Benzinga
07:10AM EST  Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis   Benzinga
07:00AM EST  Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment   GlobeNewswire Inc
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 13, 2021
07:25AM EST  The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations   Benzinga
Jan 12, 2021
04:32PM EST  Travere Therapeutics Announces That It Was Granted An Orphan Drug Designation From The FDA For The Treatment Of IgA Nephropathy   Benzinga
04:30PM EST  Travere Therapeutics Announces Orphan Drug Designation for   GlobeNewswire Inc
05:09AM EST  Travere Therapeutics on Monday Received FDA Orphan Drug Designation for Sparsentan for Treatment of immunoglobulin A (IgA) nephropathy   Benzinga
Jan 11, 2021
07:28AM EST  Travere Expects Net Product Sales For Q4 To Be $51 Mln   RTTNews
07:13AM EST  Travere Therapeutics Sees Q2 Net Products of ~$51M   Benzinga
07:00AM EST  Travere Therapeutics Provides Corporate Update and 2021 Outlook   GlobeNewswire Inc
Jan 4, 2021
04:10PM EST  Travere Therapeutics 13G Filing From Adage Capital Shows New 5.58% Stake In Co.   Benzinga
Dec 22, 2020
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 1, 2020
04:30PM EST  Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to review the Companys key pipeline programs. The event will feature presentations from external experts and the Travere Therapeutics senior management team.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC